Related Experiment Video
Updated: Jul 15, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.3K
New Potential Treatments for Resistant Hypertension
Arun Janakiraman1, Debbie L Cohen2
1Department of Medicine, Renal-Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, 1 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA, 19147, USA.
Current Cardiology Reports
|September 27, 2023
Summary
Resistant hypertension (RH) management is challenging. Emerging therapies like dual endothelin receptor antagonists and aldosterone synthase inhibitors show promise for better blood pressure control in RH patients.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Resistant hypertension (RH) is defined as blood pressure remaining elevated despite using three antihypertensive agents (including a diuretic) or four or more agents.
- Patients with RH face increased risks of cardiovascular and renal complications.
- Distinguishing true RH from apparent RH is crucial, as true RH requires a diagnosis of exclusion.
Purpose of the Study:
- To review current treatment strategies for resistant hypertension.
- To highlight emerging therapies and their potential impact on blood pressure control.
Main Methods:
- Review of current literature and clinical trial data on resistant hypertension treatments.
- Focus on novel pharmacological agents and interventional procedures.
Main Results:
- Standardized therapy for diagnosed RH includes a diuretic and often a mineralocorticoid.
- Newer agents like dual endothelin receptor antagonists and aldosterone synthase inhibitors demonstrate efficacy in trials.
- Approved medications such as SGLT2 inhibitors and finerenone, along with renal denervation, are important considerations.
Conclusions:
- Resistant hypertension treatment remains challenging, often making blood pressure goals difficult to achieve.
- Emerging therapies offer significant promise for improved blood pressure management in RH patients.
- Incorporating novel agents and procedures into treatment paradigms is essential for optimizing outcomes.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
12
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
12
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:25Antihypertensive Drugs: Direct Renin Inhibitors
667
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
667
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
190
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190